Has served as a member of our Board of Directors since 2020.
Andrew brings more than 30 years of experience in building and leading biotechnology and pharmaceutical companies.
He currently serves as Chairman of the Board of NeRRe Therapeutics and WalkSafe Chaperhome Limited. He also recently held the same role for Blueberry Therapeutics, for KaNDy Therapeutics, a biotechnology company that was acquired by Bayer for a deal value of up to $875 million in 2020, and for Wilson Therapeutics, a biopharmaceutical company acquired by Alexion Pharmaceuticals for $855 million in 2018. Prior to that, Andrew served as the President and Chief Executive Officer for Algeta. During Andrew’s leadership, Algeta’s lead product, Xofigo, was approved by the FDA and EMA for the treatment of bone metastases in castration-resistant prostate cancer patients, followed by a strong commercial launch. In February 2014, Algeta was acquired by Bayer AG for $2.9 billion. Prior to Algeta, Andrew was the Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and held several other senior commercial positions in Europe and the US having worked at AstraZeneca, Eli Lilly, Sandoz and Boots.

Has served as a member of our Board of Directors since 2008.
Hugh is founder and Chief Executive Officer of NuCana with over 30 years of experience in the biopharmaceutical industry. He also currently serves as a non-executive director of MedAnnex Ltd. He previously served as non-executive director of Thirty Holdings Ltd and Edixomed Ltd from 2009 until 2023, when it was acquired by Convatec Group. As former Chief Operating Officer of Bioenvision Inc., Hugh led the company’s operations from start-up to a global, fully integrated, Nasdaq listed biopharmaceutical company from 2002 until 2007, when it was acquired by Genzyme, now Sanofi. Before that, he held several senior commercial positions at Quantanova Ltd in 2002, Abbott Laboratories (now AbbVie Inc.) from 1995 to 2001 and Warner-Lambert Company (now Pfizer Inc.) from 1992 to 1995.
Hugh is a named inventor on over 398 patents and over 300 pending patent applications. He received an MBA from Cardiff Business School and a BSc Honours in Biology from the University of Stirling. He currently serves on the advisory board of the Scottish Lifesciences Association. He recently received a lifetime achievement award for ‘Outstanding Contribution to Life Sciences’ by the Scottish Government.

Has served as a member of our Board of Directors since 2020.
Bali is a Managing Partner at Abingworth, a leading transatlantic life sciences investment firm. He has 17 years professional experience in healthcare across a range of functions including venture investing, R&D, clinical practice and teaching. He works with the Abingworth team in the London, Boston and Menlo Park offices to source and evaluate new investment opportunities and support existing venture investments through to exit. He represents Abingworth on the boards of Spruce Biosciences (Nasdaq: SPRB), Reneo Pharmaceuticals, Wugen Inc., Ascend GmbH and Anjarium Biosciences.
Prior to joining Abingworth, Bali was a senior partner at MVM Partners LLP in London where he completed investments in and served on the boards of several companies, both public and private. Two of these were Valneva SE, a French biotechnology company traded on Euronext and Wilson Therapeutics traded in Nasdaq OMX, both also Abingworth portfolio companies. In 2018, Bali was named among Financial News’ Rising Stars in Private Equity, which celebrated 25 men and women under the age of 40 standing out in the European private equity industry. Before MVM, Bali was a member of Bain Capital’s leveraged buyout team.
Bali obtained a degree in clinical medicine from the University of Oxford and practiced general surgery at the John Radcliffe and Addenbrooke’s Hospitals in Oxford and Cambridge, respectively. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge, and has published over a dozen peer reviewed papers. He was also a Bye-Fellow in Medical Sciences at Downing College, Cambridge where he taught pathology, surgery and medicine.

Has served as a member of our Board of Directors since 2009.
Since 1994, Martin has served as the Founding Director and Chairman of Aspen Advisory Services Ltd., a London-based private investment advisory office overseeing private and publicly traded investments in North America, Europe and Asia.
Martin is non-executive director and Chairman of the Audit Committee of Spectral AI (NASDAQ: MDAI) a medical AI company, and serves as non-executive director of Kensington Green (Management) Limited, a real estate management company, Levitronix Technologies Inc., a technology company, Alturki Holding, an industrial investment and development holding company, and Saudi Readymix Concrete Company. Pro bono he serves on the International Advisory Council of Massachusetts General Hospital (MGH).
From 1992 to 1994, Martin pursued studies at the Massachusetts Institute of Technology. From 1984 to 1992, he was controller and subsequently Chief Financial Officer of Alturki Holding. Prior to that, Mr. Mellish trained at Price Waterhouse Coopers.
He was awarded an MSc from the Master of Health Care Delivery Science at Dartmouth’s Geisel School of Medicine and Tuck School of Business, an SM (Management) from the Massachusetts Institute of Technology and an MSc (Accounting) from Northeastern University.

Has served as a member of our Board of Directors since 2018.
From March 2017 to December 2020, Adam served as GW Pharmaceuticals’ UK Managing Director and Company Secretary. GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. In addition, Mr. George has served as chairman of the board of directors and chief executive officer of Psi Pharmaceuticals Ltd since December 2021 and as a member of the board of directors of Beckley Psytech Ltd since June 2021. Adam also serves as a director of PsiClone Ltd, Neurone Ltd, and Kanna Health Ltd, private pharmaceutical development companies.
Previously, Adam was GW Pharmaceutical’s Chief Financial Officer from 2012 until March 2017 and Financial Controller from 2007 to 2012. Before joining GW Pharmaceuticals, Mr. George held several senior finance roles within both public and private companies.
Adam holds a BSc in Biology from Bristol University and is a chartered accountant. He also serves as Chairman of NuCana's Audit Committee

Has served as a member of our Board of Directors since 2018.
Cyrille brings to NuCana over 40 years of experience in the pharmaceutical and biotechnology industry. Most recently, Cyrille served as Chief Executive Officer of Divlal SAS from 2020 to 2022. Previously, he served as Vice President of Medical Assessment for Sanofi’s Corporate Business Development and M&A Group, where, among other transactions, he was deeply involved in Sanofi’s acquisition of Genzyme. Prior to this role, Cyrille served as Medical Director in Japan for Sanofi.
Before joining Sanofi, Cyrille was Medical Director and Global Head of Clinical Development at Rhone Poulenc Rorer and previously worked for Takeda in a variety of operational and medical affairs roles. Cyrille received an M.D. from the University of Paris, Saint-Antoine School of Medicine and an MSc in Human Biology (major in physiology) from the Medical University of Paris.
He is a recognised expert in oncology drug development, strategic portfolio prioritisation, and business development, with extensive leadership experience at a number of global biotechnology and pharmaceutical companies.

Has served as a member of our Board of Directors since 2021.
Elliott has served as a Senior Advisor at Boston Consulting Group since May 2021 and as a Venture Partner at 5AM Ventures since April 2022.
Previously, Elliott was Senior Vice President of Research & Development, Strategy and Operations at Amgen where he was responsible for managing and executing Amgen’s R&D strategy and drug development process. Elliott also spent 17 years at Bristol-Myers Squibb (BMS) where he was Senior Vice President and Head of Specialty Development and held a range of senior positions in BMS’s research and development group. Prior to joining BMS, Elliott was a member of the Renal Division at Brigham and Women's Hospital, where he was an investigator in federally-sponsored outcomes research and industry-sponsored clinical trials. Elliott serves as a director for Omega Therapeutics, Editas Medicines (NASDAQ: EDIT) and Kinaset Therapeutics. He also served as CEO of Intrepid Alliance, a non-profit whose objective is to facilitate the development of small molecule therapeutics for future pandemic agents and as Board Chair of TransCelerate BioPharma, a non-profit focused on improving and accelerating the development of new therapeutics.
Elliott has 24 years’ experience in the clinical development and regulatory approval of investigational medicines in the biopharmaceutical industry. He received his M.D. from the Yale School of Medicine, where he was Chief Medical Resident focusing on internal medicine and nephrology and completed fellowship training in clinical research through the Robert Wood Johnson Clinical Scholars program.